Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | CPB1 | P15086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1775830 | 1.00 | ITGAL (1.00) | ITGALGAAPDE1CCTSLCTSB | |
| SCHEMBL4637583 | 0.95 | ITGAL (1.00) | ITGALGAAPDE1CCTSLCTSB | |
| SCHEMBL1776910 | 0.95 | ITGAL (1.00) | ITGALGAAPDE1CCTSLCTSB | |
| SCHEMBL1776907 | 0.95 | ITGAL (1.00) | ITGALGAAPDE1CCTSLCTSB | |
| SCHEMBL1776908 | 0.95 | ITGAL (1.00) | ITGALGAAPDE1CCTSLCTSB | |
| SCHEMBL1777812 | 0.94 | ITGAL (0.95) | ITGALGAAPDE1CCTSLCTSB | |
| SCHEMBL1777810 | 0.94 | ITGAL (0.95) | ITGALGAAPDE1CCTSLCTSB | |
| SCHEMBL1777813 | 0.94 | ITGAL (0.95) | ITGALGAAPDE1CCTSLCTSB | |
| SCHEMBL1778590 | 0.94 | ITGAL (0.94) | ITGALGAAPDE1C | |
| SCHEMBL1778591 | 0.94 | ITGAL (0.94) | ITGALGAAPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943660-B2 | 2-(carboxyalkylaminocarbonyl)-pyrrolidines as antiinflammatory, immunosupressant, or antimetastasis agents | DOMINION PHARMAKINE S.L. (ES) | 2011-05-17 | — | — | US | disclosed |
| US-20080249157-A1 | Novel Inhibitors of the Lfa-1/Icam-1 Interaction and Uses Thereof | DOMINION PHARMAKINE S.L. (ES) | 2008-10-09 | — | — | US | disclosed |
| EP-1951665-A1 | NOVEL INHIBITORS OF THE LFA-1/ICAM-1 INTERACTION, AND USES THEREOF | Dominion Pharmakine S.L. (ES) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007054128-A1 | NOVEL INHIBITORS OF THE LFA-1/ICAM-1 INTERACTION, AND USES THEREOF | DOMINION PHARMAKINE S.L. (ES) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249157-A1 | Novel Inhibitors of the Lfa-1/Icam-1 Interaction and Uses Thereof | ICAM1, VCAM1, SELL | ITGAL 12/4885GAA 627/4885PDE1C 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.